Evidence of platelet activation in hypertension

Blann, Andrew D.; Lip, Gregory Y.H.; Islim, I. F.; Beevers, D. G.

doi:10.1038/sj.jhh.1000505

Cited by 49 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased levels of plasma 9-TG decreased from 69 to 45 ng/ml after monotherapy with the ACEI quinapril for 12 weeks in hypertensive patients (21). Islim et al (3) compared the effects of antihypertensive drugs on platelet function in untreated and treated patients with hypertension and observed that the patients treated with the ACEI had significantly lower plasma j9-TG levels than did the patients treated with other kinds of antihypertensive drugs.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Antihypertensive Treatment on Platelet Function in Essential Hypertension.

Gomi¹,

Ikeda²,

Shibuya³

et al. 2000

Hypertens Res

View full text Add to dashboard Cite

To evaluate the effect of antihypertensive therapy on platelet activation in essential hypertension, the plasma levels of fl-thromboglobulin (fl-TG) were examined in 45 patients with essential hypertension and 20 age-matched normotensive control subjects. Hypertensive patients were assigned to monotherapy with one of five different antihypertensive drugs for 6 months, and the change of plasma levels of f1-TG was reexamined after the completion of the monotherapy. The plasma 19-TG increased in hypertensive patients

show abstract

Section: Discussionmentioning

confidence: 99%

“…There are several reports that suggest monotherapy with an ACEI has a beneficial effect on platelets (20)(21)(22). Increased levels of plasma 9-TG decreased from 69 to 45 ng/ml after monotherapy with the ACEI quinapril for 12 weeks in hypertensive patients (21).…”

Section: Discussionmentioning

confidence: 99%

Effects of Antihypertensive Treatment on Platelet Function in Essential Hypertension.

Gomi¹,

Ikeda²,

Shibuya³

et al. 2000

Hypertens Res

View full text Add to dashboard Cite

show abstract

“…33 Increased platelet activation has been reported in several diseases such as hypertension, congestive heart failure, or hypercholesterolemia. All these pathophysiologic states are accompanied by endothelial dysfunction, [34][35][36][37] and reduced bioavailability of endogenous NO is likely to play a crucial role in modulating platelet activation. 36 While fractalkine is not expressed by endothelial cells under physiologic conditions in vivo, 38 its expression is enhanced in vascular injury or atherosclerosis.…”

Section: Discussionmentioning

confidence: 99%

Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion

Schäfer

Schulz

Eigenthaler

et al. 2004

Blood

128

View full text Add to dashboard Cite

“…Increasing evidence suggests that hypertension confers a prothrombic state, characterized by abnormalities of endothelial function and platelet activation. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] This dysfunction is conferred by isolated systolic hypertension as well as simultaneous systolic and diastolic hypertension. 9 Consequently, investigative interest has recently focused on endothelial and platelet activation as important mediators of hypertensive vascular injury.…”

mentioning

confidence: 99%

Effects of Severe Hypertension on Endothelial and Platelet Microparticles

et al. 2003

View full text Add to dashboard Cite

Abstract-The molecular mechanisms by which extreme blood pressure elevation leads to vascular injury are not defined.To explore the hypothesis that activation of endothelium and platelets as manifested by increased concentrations of circulating endothelial microparticles and platelet microparticles could play a role in this target organ injury, we conducted a cross-sectional study of these markers in 3 groups: (1) untreated patients referred specifically for treatment of severe uncontrolled hypertension; (2) untreated patients with established mild hypertension; and (3) normotensive volunteer subjects. By ANOVA, endothelial (Pϭ0.002) and platelet (Pϭ0.01) microparticles were greatest in the severely hypertensive group. There was a significant correlation between both of these markers and blood pressure, even in the setting of multiple risk factors. Our results suggest that these markers may be useful and specific for pressure-induced endothelial and platelet activation in hypertension. Furthermore, because of the combined effects of endothelial and platelet microparticles on coagulation, leukocytes, and endothelium, it is possible that they may play a pathogenic role in mediating target organ injury in severe hypertension. Key Words: hypertension, arterial Ⅲ endothelium Ⅲ platelets Ⅲ endothelium-derived factors Ⅲ cell adhesion molecules S evere, uncontrolled hypertension is associated with high rates of target organ complications, 1-6 but the molecular mechanisms by which extreme blood pressure elevation leads to vascular injury are not well defined. Increasing evidence suggests that hypertension confers a prothrombic state, characterized by abnormalities of endothelial function and platelet activation. [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] This dysfunction is conferred by isolated systolic hypertension as well as simultaneous systolic and diastolic hypertension. 9 Consequently, investigative interest has recently focused on endothelial and platelet activation as important mediators of hypertensive vascular injury.Endothelial microparticles (EMP) are small membrane vesicles that are shed from the surface of endothelial cells in response to activation, injury, and/or apoptosis. EMP release can be caused by a number of cytokines such as interleukin-1 and tumor necrosis factor and by elevated shear pressure. [25][26][27][28][29][30] Assays for circulating EMP have recently been developed 25-26 as potential means of quantifying endothelial cell injury. EMP are also known to be elevated in thrombotic thrombocytopenic purpura, 26 a condition associated with endothelial injury, and in acute coronary syndromes. 27,30 Increased EMP release has also been associated with endothelial injury in patients with multiple sclerosis and lupus anticoagulant. 25,28 -29 Circulating platelet microparticle (PMP) concentration is a marker of platelet activation. [31][32][33] PMP are formed by platelet membrane vesicle formation and shedding. 31 PMP are known to possess procoagulant activity and are elev...

show abstract

Evidence of platelet activation in hypertension

Cited by 49 publications

References 0 publications

Effects of Antihypertensive Treatment on Platelet Function in Essential Hypertension.

Effects of Antihypertensive Treatment on Platelet Function in Essential Hypertension.

Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion

Effects of Severe Hypertension on Endothelial and Platelet Microparticles

Contact Info

Product

Resources

About